Business Wire

Ingram Micro Extends Financing Programs and Flexible Credit Options to Technology Channel Partners across Europe

Share

Ingram Micro Inc. today announced another wave of financial services to help channel partners solve for the cash crunch created by the COVID-19 pandemic, while meeting the technology needs of businesses and consumers worldwide. Readily available throughout Europe, the new and enhanced Ingram Micro Financial Solutions offerings include flexible, low-interest and long-term financing solutions, as well as extended credit terms, deferred payments, as-a-service models and pay-as-you-go options.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519006025/en/

Mark Snider, Executive Vice President and Group President, EMEA, Ingram Micro (Photo: Business Wire)

Mark Snider, Executive Vice President and Group President, EMEA, Ingram Micro (Photo: Business Wire)

“Ingram Micro is generating new ways to help our channel partners, and the businesses they serve, stay strong, agile and fiscally smart, so they can come out of this crisis in a position of strength,” said Mark Snider, Executive Vice President and Group President, EMEA, Ingram Micro. “Each country throughout Europe is unique, yet many of our channel partners, and their business customers, face similar fiscal and cash flow concerns, due to the economic impact of COVID-19. Fortunately, financial services are one of the many areas where Ingram Micro is clearly differentiated and able to help our channel partners at scale locally and globally.”

In addition, Ingram Micro is also helping channel partners identify and address the European marketplace’s work from home (WFH) and distance learning requirements, as well as cybersecurity-as-a-service, data centre solutions and cloud-based services. “COVID-19 prioritized digital transformation overnight, placing Ingram Micro and our channel partners in a position to serve and help keep the world securely connected and moving forward together,” Snider continued.

John Mayer, Vice President, Channel Financing, Ingram Micro Europe and Asia Pacific adds, “Our financing options are structured to address the present and give businesses a way to prepare for the future—helping our channel partners and the businesses they serve to create and preserve cash, protect credit lines, and align payments to the current business environment, until business activity is more stable and growing.”

Throughout Europe, channel partners are taking advantage of the new Ingram Micro Financial Solutions programs including the purchase and lease back of IT solutions. “Having the flexibility to lease, buy or defer payments is changing the conversation and allowing us to get our customers the technology they need in real-time without taking on the financial risk or using our own cash to close the deal,” says Ingram Micro channel partner Brian Dunleavy, Commercial Director, Viadex UK Ltd.

Channel partners in Europe can also access longer-term financing solutions through IMFS. These solutions will align payments with revised budget objectives and places the needed capital quickly back into business cash reserves. Similarly, Ingram Micro’s “as a service” finance offerings are making it easier for channel partners interested in expanding their managed services business and cloud practices.

“As-a-service financing solutions are easier on budgets, versus capital-intensive one-time technology purchases. This model also establishes a more profitable recurring revenue stream for channel partners,” says Kris Mees, Vice President Finance and International CFO, Ingram Micro Europe. “With the rising adoption of cloud and managed services, we expect our “as-a-service” financing options to gain more traction, and we’re ready to give channel partners, and the businesses they serve the support they need.”

Additionally, Ingram Micro credit and financial experts are working one-on-one with qualified channel partners across Europe to determine what other offerings may be available to them including custom financing solutions and additional credit capacity. Ingram Micro Europe’s standard suite of financial services and solutions includes:

  • Traditional leasing
  • Advanced solutions financing
  • Managed services financing
  • Private-label agreements
  • And, financial structures such as fair market value, full pay out, technology equipment rentals, pay-as-you-grow solutions, and guaranteed purchase options

“Today and every day, helping our channel partners understand the financing options available to them and their customers is equally as important as helping them decide on what technology solutions and services are best suited for the needs of their customers,” concludes Mayer. “Together with our channel partners, we will continue to grow and create sustainable business value that leads to an exceptional experience for them and their customers.”

Ingram Micro Financial Solutions operates globally offering financial programs and services across the Americas, Asia Pacific and Europe. To find out more about the financial solutions in Europe, please contact: https://financing.ingrammicro.eu/.

About Ingram Micro

Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unparalleled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.

Contact information

Marie Rourke
WhiteFox Marketing Inc.
marie@whitefoxpr.com
714-292-2199

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom